DaVita Inc. (DVA)
|Net Income (ttm)||863.67M|
|Day's Range||111.37 - 112.76|
|52-Week Range||84.14 - 136.48|
|Price Target||140.33 (+25.1%)|
|Est. Earnings Date||Oct 28, 2021|
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. ... [Read more...]
In 2020, DaVita's revenue was $11.55 billion, an increase of 1.42% compared to the previous year's $11.39 billion. Earnings were $773.64 million, a decrease of -4.60%.Financial Statements
According to 12 analysts, the average rating for DaVita stock is "Hold." The 12-month stock price forecast is 140.33, which is an increase of 25.06% from the latest price.
DENVER, Oct. 11, 2021 /PRNewswire/ -- DaVita furthers commitment to climate action goals with validation from the Science Based Targets initiative (SBTi). The organization has approved two goals: Supply...
DENVER, Sept. 16, 2021 /PRNewswire/ -- During Nephrology Nurses Week, DaVita Kidney Care begins a new chapter for its nursing program by announcing Tina Livaudais as the kidney care provider's chief nur...
DENVER, Sept. 9, 2021 /PRNewswire/ -- DaVita Inc. announced today that its Board of Directors appointed a new independent director, Gregory Moore, M.D.
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 23.36% and 1.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of DaVita (NYSE:DVA) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 35.38% year over year to $2.64, which beat the esti...
DENVER, Aug. 3, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2021. For the quarter, diluted earnings per share from continuing op...
Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.
DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DENVER, July 21, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 3, 2021, at 5:00 p.m. ...
These stocks check all the right boxes for the Oracle of Omaha.
DVA vs. AMED: Which Stock Is the Better Value Option?
Warren Buffett's Berkshire Hathaway Inc. (NYSE: BRK-B) portfolio includes nearly four dozen stocks.
Healthcare stocks with long-term growth visibility can be important additions to investment portfolio when inflation runs high.
Investors continue to be optimistic about DaVita (DVA) on its slew of tie-ups and strength in its kidney care business.
According to the All-in-One Screener, a Premium feature of GuruFocus, four stocks in Berkshire Hathaway Inc.'s ( BRK.A , Financial)( BRK.B , Financial) equity portfolio that have high profitability and ...